ONCO — Oncopeptides AB Balance Sheet
0.000.00%
Last trade - 00:00
- SEK488.37m
- SEK451.63m
- SEK35.22m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 926 | 840 | 362 | 345 | 173 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 6.98 | 23.2 | 38 | 17.3 | 27.1 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 971 | 895 | 412 | 364 | 203 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 17.2 | 38.3 | 24.7 | 20.4 | — |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 993 | 947 | 439 | 385 | 238 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 165 | 354 | 225 | 85.7 | 44.9 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 196 | 370 | 229 | 91 | 182 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 797 | 577 | 211 | 294 | 56.8 |
Total Liabilities & Shareholders' Equity | 993 | 947 | 439 | 385 | 238 |
Total Common Shares Outstanding |